FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317362217> ?p ?o ?g. }

• W2317362217 endingPage "712" @default.
• W2317362217 startingPage "705" @default.
• W2317362217 abstract "BackgroundThe consistency of fixed airflow limitation status during treatment in patients with asthma is unknown.ObjectiveThe objective of this study was to determine the consistency of fixed airflow obstruction (FAO) status during treatment and effects on treatment response.MethodsThis post hoc analysis from a 12-week study (NCT00652002) assessed patients aged 12 years or more with moderate-to-severe asthma randomized to twice-daily budesonide/formoterol (BUD/FM) via pressurized metered-dose inhaler (pMDI) 320/9 μg, BUD pMDI 320 μg, FM 9 μg via dry-powder inhaler, or placebo. FAO status was assessed postbronchodilator at screening and after study drug administration at weeks 2, 6, and 12 via the forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) ratio < lower limit of normal (LLN) (FAO+) or ≥ LLN (FAO−). Patients with persistent FAO− and FAO+ retained their screening FAO status at all visits. Patients with inconsistent FAO changed categories at least once during the study. Assessments included early withdrawal due to predefined worsening asthma events (PAEs), lung function, and symptoms.ResultsOf 386 patients, 29% had persistent FAO+, 31% inconsistent FAO, and 40% persistent FAO−. PAEs were lowest in the FAO− group overall and with BUD/FM treatment in patients with FAO+ and inconsistent FAO. Baseline demographics and treatment responses of the inconsistent FAO group were most similar to the FAO+ group. The greatest improvements in asthma control days and use of rescue medications were seen with BUD/FM treatment, regardless of FAO status.ConclusionsApproximately one third of patients with moderate-to-severe asthma in this study had inconsistent FAO, and their treatment responses were most similar to patients with FAO+. Regardless of FAO status, patients treated with BUD/FM experienced the most improved treatment responses and fewest withdrawals due to PAEs. The consistency of fixed airflow limitation status during treatment in patients with asthma is unknown. The objective of this study was to determine the consistency of fixed airflow obstruction (FAO) status during treatment and effects on treatment response. This post hoc analysis from a 12-week study (NCT00652002) assessed patients aged 12 years or more with moderate-to-severe asthma randomized to twice-daily budesonide/formoterol (BUD/FM) via pressurized metered-dose inhaler (pMDI) 320/9 μg, BUD pMDI 320 μg, FM 9 μg via dry-powder inhaler, or placebo. FAO status was assessed postbronchodilator at screening and after study drug administration at weeks 2, 6, and 12 via the forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) ratio < lower limit of normal (LLN) (FAO+) or ≥ LLN (FAO−). Patients with persistent FAO− and FAO+ retained their screening FAO status at all visits. Patients with inconsistent FAO changed categories at least once during the study. Assessments included early withdrawal due to predefined worsening asthma events (PAEs), lung function, and symptoms. Of 386 patients, 29% had persistent FAO+, 31% inconsistent FAO, and 40% persistent FAO−. PAEs were lowest in the FAO− group overall and with BUD/FM treatment in patients with FAO+ and inconsistent FAO. Baseline demographics and treatment responses of the inconsistent FAO group were most similar to the FAO+ group. The greatest improvements in asthma control days and use of rescue medications were seen with BUD/FM treatment, regardless of FAO status. Approximately one third of patients with moderate-to-severe asthma in this study had inconsistent FAO, and their treatment responses were most similar to patients with FAO+. Regardless of FAO status, patients treated with BUD/FM experienced the most improved treatment responses and fewest withdrawals due to PAEs." @default.
• W2317362217 created "2016-06-24" @default.
• W2317362217 creator A5037723579 @default.
• W2317362217 creator A5037818978 @default.
• W2317362217 creator A5062711392 @default.
• W2317362217 creator A5085931471 @default.
• W2317362217 creator A5090310464 @default.
• W2317362217 date "2016-07-01" @default.
• W2317362217 modified "2023-09-26" @default.
• W2317362217 title "Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma" @default.
• W2317362217 cites W128731631 @default.
• W2317362217 cites W1959938853 @default.
• W2317362217 cites W1997884321 @default.
• W2317362217 cites W2002361709 @default.
• W2317362217 cites W2018968829 @default.
• W2317362217 cites W2021339739 @default.
• W2317362217 cites W2032080656 @default.
• W2317362217 cites W2045185638 @default.
• W2317362217 cites W2049404931 @default.
• W2317362217 cites W2064113839 @default.
• W2317362217 cites W2066968375 @default.
• W2317362217 cites W2071379618 @default.
• W2317362217 cites W2103031437 @default.
• W2317362217 cites W2108678383 @default.
• W2317362217 cites W2112904080 @default.
• W2317362217 cites W2130608493 @default.
• W2317362217 cites W2145153937 @default.
• W2317362217 cites W2789378292 @default.
• W2317362217 cites W4236639597 @default.
• W2317362217 doi "https://doi.org/10.1016/j.jaip.2016.02.014" @default.
• W2317362217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27039236" @default.
• W2317362217 hasPublicationYear "2016" @default.
• W2317362217 type Work @default.
• W2317362217 sameAs 2317362217 @default.
• W2317362217 citedByCount "9" @default.
• W2317362217 countsByYear W23173622172017 @default.
• W2317362217 countsByYear W23173622172019 @default.
• W2317362217 countsByYear W23173622172020 @default.
• W2317362217 countsByYear W23173622172021 @default.
• W2317362217 countsByYear W23173622172022 @default.
• W2317362217 countsByYear W23173622172023 @default.
• W2317362217 crossrefType "journal-article" @default.
• W2317362217 hasAuthorship W2317362217A5037723579 @default.
• W2317362217 hasAuthorship W2317362217A5037818978 @default.
• W2317362217 hasAuthorship W2317362217A5062711392 @default.
• W2317362217 hasAuthorship W2317362217A5085931471 @default.
• W2317362217 hasAuthorship W2317362217A5090310464 @default.
• W2317362217 hasBestOaLocation W23173622171 @default.
• W2317362217 hasConcept C105922876 @default.
• W2317362217 hasConcept C126322002 @default.
• W2317362217 hasConcept C142724271 @default.
• W2317362217 hasConcept C165637977 @default.
• W2317362217 hasConcept C204787440 @default.
• W2317362217 hasConcept C27081682 @default.
• W2317362217 hasConcept C2776042228 @default.
• W2317362217 hasConcept C2776136866 @default.
• W2317362217 hasConcept C2777419714 @default.
• W2317362217 hasConcept C2777450039 @default.
• W2317362217 hasConcept C2777714996 @default.
• W2317362217 hasConcept C2778333281 @default.
• W2317362217 hasConcept C2779871671 @default.
• W2317362217 hasConcept C2780261241 @default.
• W2317362217 hasConcept C2780667556 @default.
• W2317362217 hasConcept C3018587741 @default.
• W2317362217 hasConcept C42219234 @default.
• W2317362217 hasConcept C55520419 @default.
• W2317362217 hasConcept C71924100 @default.
• W2317362217 hasConcept C75603125 @default.
• W2317362217 hasConceptScore W2317362217C105922876 @default.
• W2317362217 hasConceptScore W2317362217C126322002 @default.
• W2317362217 hasConceptScore W2317362217C142724271 @default.
• W2317362217 hasConceptScore W2317362217C165637977 @default.
• W2317362217 hasConceptScore W2317362217C204787440 @default.
• W2317362217 hasConceptScore W2317362217C27081682 @default.
• W2317362217 hasConceptScore W2317362217C2776042228 @default.
• W2317362217 hasConceptScore W2317362217C2776136866 @default.
• W2317362217 hasConceptScore W2317362217C2777419714 @default.
• W2317362217 hasConceptScore W2317362217C2777450039 @default.
• W2317362217 hasConceptScore W2317362217C2777714996 @default.
• W2317362217 hasConceptScore W2317362217C2778333281 @default.
• W2317362217 hasConceptScore W2317362217C2779871671 @default.
• W2317362217 hasConceptScore W2317362217C2780261241 @default.
• W2317362217 hasConceptScore W2317362217C2780667556 @default.
• W2317362217 hasConceptScore W2317362217C3018587741 @default.
• W2317362217 hasConceptScore W2317362217C42219234 @default.
• W2317362217 hasConceptScore W2317362217C55520419 @default.
• W2317362217 hasConceptScore W2317362217C71924100 @default.
• W2317362217 hasConceptScore W2317362217C75603125 @default.
• W2317362217 hasIssue "4" @default.
• W2317362217 hasLocation W23173622171 @default.
• W2317362217 hasLocation W23173622172 @default.
• W2317362217 hasOpenAccess W2317362217 @default.
• W2317362217 hasPrimaryLocation W23173622171 @default.
• W2317362217 hasRelatedWork W1992641028 @default.
• W2317362217 hasRelatedWork W2062078911 @default.
• W2317362217 hasRelatedWork W2091948488 @default.
• W2317362217 hasRelatedWork W2097762785 @default.
• W2317362217 hasRelatedWork W2130156739 @default.

• next